X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs LUPIN - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA LUPIN SUN PHARMA/
LUPIN
 
P/E (TTM) x 32.5 41.9 77.6% View Chart
P/BV x 2.7 2.5 107.2% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 SUN PHARMA   LUPIN
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
LUPIN
Mar-19
SUN PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs701986 71.0%   
Low Rs433720 60.1%   
Sales per share (Unadj.) Rs110.4369.5 29.9%  
Earnings per share (Unadj.) Rs11.013.4 81.9%  
Cash flow per share (Unadj.) Rs17.237.4 46.1%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs158.8303.7 52.3%  
Shares outstanding (eoy) m2,399.26452.49 530.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.12.3 222.3%   
Avg P/E ratio x51.663.6 81.1%  
P/CF ratio (eoy) x32.922.8 144.2%  
Price / Book Value ratio x3.62.8 127.1%  
Dividend payout %18.20-   
Avg Mkt Cap Rs m1,360,021386,064 352.3%   
No. of employees `00017.817.7 100.6%   
Total wages/salary Rs m53,67131,513 170.3%   
Avg. sales/employee Rs Th14,890.99,453.8 157.5%   
Avg. wages/employee Rs Th3,017.11,782.0 169.3%   
Avg. net profit/employee Rs Th1,480.6343.0 431.7%   
INCOME DATA
Net Sales Rs m264,895167,182 158.4%  
Other income Rs m8,3883,640 230.4%   
Total revenues Rs m273,282170,822 160.0%   
Gross profit Rs m56,08128,822 194.6%  
Depreciation Rs m14,99810,850 138.2%   
Interest Rs m5,1763,078 168.1%   
Profit before tax Rs m44,29518,534 239.0%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m-9,505-3,400 279.6%   
Tax Rs m8,4529,017 93.7%   
Profit after tax Rs m26,3386,066 434.2%  
Gross profit margin %21.217.2 122.8%  
Effective tax rate %19.148.7 39.2%   
Net profit margin %9.93.6 274.1%  
BALANCE SHEET DATA
Current assets Rs m316,359138,536 228.4%   
Current liabilities Rs m198,64361,299 324.1%   
Net working cap to sales %44.446.2 96.2%  
Current ratio x1.62.3 70.5%  
Inventory Days Days9584 113.2%  
Debtors Days Days108112 95.8%  
Net fixed assets Rs m213,178127,516 167.2%   
Share capital Rs m2,399905 265.1%   
"Free" reserves Rs m378,606136,517 277.3%   
Net worth Rs m381,006137,422 277.3%   
Long term debt Rs m17,72166,417 26.7%   
Total assets Rs m643,028279,494 230.1%  
Interest coverage x9.67.0 136.1%   
Debt to equity ratio x00.5 9.6%  
Sales to assets ratio x0.40.6 68.9%   
Return on assets %4.93.3 149.8%  
Return on equity %6.94.4 156.6%  
Return on capital %10.08.9 112.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81659,414 68.7%   
Fx outflow Rs m30,14322,282 135.3%   
Net fx Rs m10,67337,132 28.7%   
CASH FLOW
From Operations Rs m39,07216,660 234.5%  
From Investments Rs m-33,708-32,825 102.7%  
From Financial Activity Rs m-15,3937,441 -206.9%  
Net Cashflow Rs m-7,359-8,724 84.4%  

Share Holding

Indian Promoters % 63.7 46.6 136.7%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 5.1 11.3 45.4%  
FIIs % 23.0 31.9 72.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 10.1 82.2%  
Shareholders   133,026 98,259 135.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  AUROBINDO PHARMA  PFIZER  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Wipro's Q1FY20 Result, Crude Oil Prices, and Top Cues in Focus Today(Pre-Open)

On Wednesday, share markets in India traded on a positive note most of the day and ended marginally higher.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jul 17, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS